Oxford Asset Management’s Precision BioSciences DTIL Stock Holding History

Oxford Asset Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-784	Closed	-$327K	–	523
2019 Q4	$327K	Buy	+784	New	+$246K	0.01%	1403
2019 Q2	–	Sell	-3,441	Closed	-$1.85M	–	1764
2019 Q1	$1.85M	Buy	+3,441	New	+$1.83M	0.04%	619

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

ACWM

Adams Chetwood Wealth Management Durham, North Carolina $176M AUM 8.48% 1-Year Est. Return

Oxford Asset Management's DTIL Position: Q1 2020 in Review

Oxford Asset Management sold out of Precision BioSciences (DTIL) in Q1 2020, closing a stake of 784 shares — an estimated $327K sold.

Oxford Asset Management first reported a position in DTIL in Q1 2019 and held it in 2 quarters. The position peaked at $1.85M in Q1 2019. 109 funds tracked by Wall St. Rank hold DTIL as of Q1 2020.

Oxford Asset Management reported no remaining Precision BioSciences position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 784 Precision BioSciences shares in Q1 2020, an estimated $327K.
Oxford Asset Management first reported a position in Precision BioSciences in Q1 2019 and held it in 2 quarters.
Oxford Asset Management's Precision BioSciences position peaked at $1.85M in Q1 2019.
109 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.